Journal of Innovations in Pharmaceutical and Biological Sciences
Read the article
Visual summary · Journal of Innovations in Pharmaceutical and Biological Sciences

Deciphering the Anticancer Mechanism of Naringenin and Berberine in Breast Cancer via Network Pharmacology and Molecular Docking

Shaikh Mo Sarosh, Shaikh Moin, Shaikh Mehmood Dawood

The question

What therapeutic potential do Naringenin and Berberine show against breast cancer, and at which targets?

  • Breast cancer is among the commonest malignancies in women around the world and still a leading cause of illness and death from cancer.
  • Despite advances in conventional therapy, resistance to drugs, toxicity through the body and poor selectivity keep limiting how well it works.
  • Safer molecules from natural sources able to act on several targets have therefore drawn much scientific interest.

What was done

Twocompounds studied: Naringenin and Berberine
GeneCardssource of the breast-cancer genes
SRCand PIK3CA, the two docking targets
  • Network pharmacology and molecular docking were used together to examine what the two compounds might do against breast cancer.
  • Likely targets of the compounds were found with SwissTargetPrediction and PubChem; the genes tied to breast cancer were sought in the GeneCards database.
  • Protein-protein interaction analysis and studies of pathway enrichment followed.

Key findings

Finding 1 of 4
SRC
among the critical targets the network work found

Critical targets came out of that work, among them SRC and the PIK3CA, PIK3CB and PIK3CD genes, CYP3A4 and IGF1R, ESR1 and KDR. These bear on the control of oxidative stress, on cell growth, on endocrine resistance and on the progress of cancer.

Finding 2 of 4
-6.6 kcal/mol
Berberine's docking score against SRC

Berberine's docking score at SRC was -6.6 kcal/mol, and at PIK3CA -6.2 kcal/mol.

Finding 3 of 4
-6.9 kcal/mol
Naringenin's docking score against PIK3CA

Naringenin's scores were -5.8 kcal/mol at SRC and -6.9 kcal/mol at PIK3CA, set beside the reference medication Alpelisib.

Finding 4 of 4
Favorable
binding of both compounds with SRC and with PIK3CA

The docking work showed favorable binding interactions for both compounds with SRC (7A3D) and with PIK3CA (2V1Y).

Why it matters

  • The authors say the data point to anticancer potential for these plant chemicals against breast cancer, through action at several targets.
  • The work joined network pharmacology to molecular docking, which gave the binding at SRC and PIK3CA.

How to cite

Shaikh Mo Sarosh, Shaikh Moin, Shaikh Mehmood Dawood. Deciphering the Anticancer Mechanism of Naringenin and Berberine in Breast Cancer via Network Pharmacology and Molecular Docking. Journal of Innovations in Pharmaceutical and Biological Sciences. 2026;13(01):24-34. https://doi.org/10.56511/jipbs.2026.13104

Open the article